Treatt reshuffles leadership, Randhawa to take interim MD role
Natural extracts and ingredients business Treatt Plc said on Monday that Manprit Randhawa will broaden his remit to interim group managing director, with effect from 1 January.
Randhawa, who joined the company in September as interim CFO, will now oversee business performance and lead Treatt's management team during the transition. He will report directly to the board and become a director of the company, working alongside outgoing chief executive David Shannon to complete a handover this month.
Treatt also said that Kelly Gordon, currently group finance director and head of investor relations, will assume operational responsibility for Treatt's finance function and reporting requirements. Gordon will report to Randhawa, who will retain oversight of Treatt's financial strategy.
Chairman Vijay Thakrar said: "Manprit has made a strong contribution since joining in September. He has quickly grasped our key business issues and has earned the confidence of our employees, leadership team and the board, positioning him well to take on the Interim Group MD role.
"We are confident that this new interim management structure, with Manprit working alongside our strong leadership team, will steward the business well until a new CEO is in place."
As of 0825 GMT, Treatt shares were down 0.73% at 211.44p.
Reporing by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
